Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Importance: The development of a coronavirus disease 2019 (COVID-19) vaccine has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. Objective: To examine the factors associated with survey participants' self-reported likelihood of selecting and receiving a hypothetical COVID-19 vaccine. Design, Setting, and Participants: A survey study of a nonprobability convenience sample of 2000 recruited participants including a choice-based conjoint analysis was conducted to estimate respondents' probability of choosing a vaccine and willingness to receive vaccination. Participants were asked to evaluate their willingness to receive each hypothetical vaccine individually. The survey presented respondents with 5 choice tasks. In each, participants evaluated 2 hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, vaccine B, or neither vaccine. Vaccine attributes included efficacy, protection duration, major adverse effects, minor adverse effects, US Food and Drug Administration (FDA) approval process, national origin of vaccine, and endorsement. Levels of each attribute for each vaccine were randomly assigned, and attribute order was randomized across participants. Survey data were collected on July 9, 2020. Main Outcomes and Measures: Average marginal component effect sizes and marginal means were calculated to estimate the relationship between each vaccine attribute level and the probability of the respondent choosing a vaccine and self-reported willingness to receive vaccination. Results: A total of 1971 US adults responded to the survey (median age, 43 [interquartile range, 30-58] years); 999 (51%) were women, 1432 (73%) White, 277 (14%) were Black, and 190 (10%) were Latinx. An increase in efficacy from 50% to 70% was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.06-0.09), and an increase from 50% to 90% was associated with a higher probability of choosing a vaccine (coefficient, 0.16; 95% CI, 0.15-0.18). An increase in protection duration from 1 to 5 years was associated with a higher probability of choosing a vaccine (coefficient, 0.05 95% CI, 0.04-0.07). A decrease in the incidence of major adverse effects from 1 in 10 000 to 1 in 1 000 000 was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.05-0.08). An FDA emergency use authorization was associated with a lower probability of choosing a vaccine (coefficient, -0.03; 95% CI, -0.04 to -0.01) compared with full FDA approval. A vaccine that originated from a non-US country was associated with a lower probability of choosing a vaccine (China: -0.13 [95% CI, -0.15 to -0.11]; UK: -0.04 [95% CI, -0.06 to -0.02]). Endorsements from the US Centers for Disease Control and Prevention (coefficient, 0.09; 95% CI, 0.07-0.11) and the World Health Organization (coefficient, 0.06; 95% CI, 0.04-0.08), compared with an endorsement from President Trump were associated with higher probabilities of choosing a vaccine. Analyses of participants' willingness to receive each vaccine when assessed individually yielded similar results. An increase in efficacy from 50% to 90% was associated with a 10% higher marginal mean willingness to receive a vaccine (from 0.51 to 0.61). A reduction in the incidence of major side effects was associated with a 4% higher marginal mean willingness to receive a vaccine (from 0.54 to 0.58). A vaccine originating in China was associated with a 10% lower willingness to receive a vaccine vs one developed in the US (from 0.60 to 0.50) Endorsements from the Centers for Disease Control and Prevention and World Health Organization were associated with increases in willingness to receive a vaccine (7% and 6%, respectively) from a baseline endorsement by President Trump (from 0.52 to 0.59 and from 0.52 to 0.58, respectively). Conclusions and Relevance: In this survey study of US adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self-reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hainmueller, J., Hopkins, D. J., & Yamamoto, T. (2014) · Political Analysis · doi:10.1093/pan/mpt024 · Cited by 1,990 · cited 1×
“Educational attainment Less than high school 34 (2) High school/GED 410 (21) Some college 583 (30) 4-y College degree 469 (24) Graduate school 475 (24)”
BackgroundThe State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey
Larson, H. J., de Figueiredo, A., Xiahong, Z., Schulz, W. S., Verger, P., Johnston, I. G., Cook, A. R., & Jones, N. S. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.042 · Cited by 1,264
Coppock, A., & McClellan, O. A. (2019) · Research & Politics · doi:10.1177/2053168018822174 · Cited by 987
Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide
de Bekker-Grob, E. W., Donkers, B., Jonker, M. F., & Stolk, E. A. (2015) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-015-0118-z · Cited by 925
Measuring Subgroup Preferences in Conjoint Experiments
Leeper, T. J., Hobolt, S. B., & Tilley, J. (2020) · Political Analysis · doi:10.1017/pan.2019.30 · Cited by 846
Rapid COVID-19 vaccine development
Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771
Commercial Use of Conjoint Analysis: A Survey
Cattin, P., & Wittink, D. R. (1982) · Journal of Marketing · doi:10.1177/002224298204600308 · Cited by 692
Summary Report of the AAPOR Task Force on Non-probability Sampling
Baker, R., Brick, J. M., Bates, N. A., Battaglia, M., Couper, M. P., Dever, J. A., Gile, K. J., & Tourangeau, R. (2013) · Journal of Survey Statistics and Methodology · doi:10.1093/jssam/smt008 · Cited by 652
Research synthesis: AAPOR report on online panels
Prepared for the AAPOR Executive Council by a Task Force operating under the auspices of the AAPOR Standards Committee, W. M. I., Baker, R., Blumberg, S. J., Brick, J. M., Couper, M. P., Courtright, M., Dennis, J. M., Dillman, D., Frankel, M. R., Garland, P., et al. (2010) · Public Opinion Quarterly · doi:10.1093/poq/nfq048 · Cited by 584
Quaife, M., Terris-Prestholt, F., Di Tanna, G. L., & Vickerman, P. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-0954-6 · Cited by 371
Cited by
A global database of COVID-19 vaccinations
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01122-8 · Cited by 1,974
Vaccine hesitancy in the era of COVID-19
Troiano, G., & Nardi, A. (2021) · Public Health · doi:10.1016/j.puhe.2021.02.025 · Cited by 1,329
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries
(2021) · doi:10.1038/s41591-021-01454-y · Cited by 1,105
Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review
Lin, C., Tu, P., & Beitsch, L. M. (2020) · Vaccines · doi:10.3390/vaccines9010016 · Cited by 839
Schwarzinger, M., Watson, V., Arwidson, P., Alla, F., & Luchini, S. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00012-8 · Cited by 778
Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study
Robertson, E., Reeve, K. S., Niedzwiedz, C. L., Moore, J., Blake, M., Green, M., Katikireddi, S. V., & Benzeval, M. J. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.03.008 · Cited by 690
Behavioural nudges increase COVID-19 vaccinations
Dai, H., Saccardo, S., Han, M. A., Roh, L., Raja, N., Vangala, S., Modi, H., Pandya, S., Sloyan, M., & Croymans, D. M. (2021) · Nature · doi:10.1038/s41586-021-03843-2 · Cited by 462
COVID-19 Vaccine Hesitancy—A Scoping Review of Literature in High-Income Countries
Aw, J., Seng, J. J. B., Seah, S. S. Y., & Low, L. L. (2021) · Vaccines · doi:10.3390/vaccines9080900 · Cited by 421
Cascini, F., Pantovic, A., Al-Ajlouni, Y., Failla, G., & Ricciardi, W. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101113 · Cited by 396
Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective
Latkin, C. A., Dayton, L., Yi, G., Konstantopoulos, A., & Boodram, B. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.113684 · Cited by 386
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear
Willis, D. E., Andersen, J. A., Bryant‐Moore, K., Selig, J. P., Long, C. R., Felix, H. C., Curran, G. M., & McElfish, P. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.13077 · Cited by 377
Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review
Joshi, A., Kaur, M., Kaur, R., Grover, A., Nash, D., & El-Mohandes, A. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.698111 · Cited by 351
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy
Finney Rutten, L. J., Zhu, X., Leppin, A. L., Ridgeway, J. L., Swift, M. D., Griffin, J. M., St Sauver, J. L., Virk, A., & Jacobson, R. M. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.024 · Cited by 301
COVID‐19 vaccination intention in the first year of the pandemic: A systematic review
Al‐Amer, R., Maneze, D., Everett, B., Montayre, J., Villarosa, A. R., Dwekat, E., & Salamonson, Y. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.15951 · Cited by 276
Thompson, H. S., Manning, M., Mitchell, J., Kim, S., Harper, F. W. K., Cresswell, S., Johns, K., Pal, S., Dowe, B., Tariq, M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11629 · Cited by 269
COVID-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population
Al-Qerem, W. A., & Jarab, A. S. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.632914 · Cited by 266
Benham, J. L., Atabati, O., Oxoby, R. J., Mourali, M., Shaffer, B., Sheikh, H., Boucher, J.-C., Constantinescu, C., Parsons Leigh, J., Ivers, N. M., et al. (2021) · JMIR Public Health and Surveillance · doi:10.2196/30424 · Cited by 67
“Both low [10,19,20,30] and high [32] education level have been associated with COVID-19 vaccine hesitancy, while lower household income has more consistently been associated with vaccine hesitancy [10,18,30].”
Porteny, T., Corlin, L., Allen, J. D., Monahan, K., Acevedo, A., Stopka, T. J., Levine, P., & Ladin, K. (2022) · BMC Public Health · doi:10.1186/s12889-022-12633-y · Cited by 14
Vaccine-induced protection in aging adults and pandemic response
Schenkelberg, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.090 · Cited by 11
“In the US, a recent study found that vaccine efficacy was the single most important indicator of vaccine acceptanced only 61% of those surveyed indicating they would take a vaccine of 90% efficacy, with acceptance dropping as efficacy declines [13].”
Ridda, I., Chamberlain, R., Haber, R., & Rashid, H. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903880 · Cited by 2
“that American public trusted expert advice from national public health bodies [12], and that endorsement from CDC was associated with 7% increase in willingness to receive a vaccine from a baseline endorsement [13].”
Background
Metadata
- Authors
- Kreps, S., Prasad, S., Brownstein, J. S., Hswen, Y., Garibaldi, B. T., Zhang, B., & Kriner, D. L.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-10-20
- Volume
- 3
- Issue
- 10
- Pages
- e2025594
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3092748982
- Cited by
- 732
- References
- 27
- FWCI
- 81.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.